Hints and tips:
Related Special Reports
...David Moore, vice-president for corporate development, added that the company would focus on acquisitions in diabetes and obesity, ideally in the early stage of development....
...It has also worked on drug development for US pharma company Johnson & Johnson, Danish biotech group Genmab and British biotech Iksuda therapeutics....
...Since the third quarter of 2023 when it had 82 new drugs in development, the company has jettisoned 16 drugs and added 12 others, including the weight-loss drug it gained through its $3.1bn acquisition of...
...The company, which provided lixisenatide free of charge to the French research but did not sponsor it, welcomed the results....
...It has pledged to double funding for dementia research to £160mn a year by 2025....
...Susan Galbraith, executive vice-president of oncology research and development at AstraZeneca, said there was an “opportunity to improve” on existing drugs in the area and that the Fusion acquisition would...
...Martin Holst Lange, head of development at Novo Nordisk, said that Cardior’s drug had the “potential to become a first-in-class therapy designed to halt or partially reverse the course of disease for people...
...Developing new antibiotics is often unattractive for pharmaceutical companies, as research and development costs are high but their use is designed to be limited to reduce the risk of the product driving...
...Treatments like this come with large upfront research and development costs but, by preventing chronic diseases, could lead to long-term savings: the yearly costs of asthma in the US alone are $56bn, mainly...
...Dr Matthew Hobbs, director of research at Prostate Cancer UK, said such changes had “made the process safer and more accurate” but better evidence was needed to understand their full impact....
...including medical companies....
...A dearth of career scientists and public funding risks undermining efforts to use technological breakthroughs to tackle the biggest health threats, the head of a leading international research organisation...
...According to a European Commission analysis of the world’s 2,500 highest spending companies in research and development published in 2023, 12 per cent of leading companies investing in health research are...
...The company has found that the technology can reduce both the time and cost of the pre-clinical testing phase of drug development by 45 per cent, Asif Hasan, co-founder of Quantiphi told me....
...This would result in FDA action being delayed beyond the first quarter, the company said in its statement....
...The company would present more precise survival data from the Tagrisso trial at a conference later this year, she added....
...Jodie Keane Senior Research Fellow ODI (Formerly Overseas Development Institute), London SE1, UK...
...“Pain could be analogous to another GLP-1 scenario,” says Hartaj Singh, a biotech analyst at equity research company Oppenheimer — referring to the hormone targeted by the weight-loss drugs....
...US federal prosecutors are also probing an Adani company and the group’s founder for potential bribery violations....
...About 1,000 people in England would have been eligible for the treatment, according to estimates by the watchdog and companies....
...However, the recent coronavirus pandemic — despite all the other the harm it caused — has brought two positive developments....
...He sold off assets in non-core areas to invest heavily in research and development, plus fund acquisitions. There were setbacks, including criticism over its accounting practices....
...In 2022/23, NIHR research expenditure for all cancers was £121.8mn.”...
...other drug development....
...“The top-level decision many companies are making is: should we use an LLM and which should we use?” said Rishi Bommasani, who leads a team at the Stanford Center for Research on Foundation Models....
International Edition